Identification of miRNA modulators to PARP inhibitor response

DNA Repair

Volumn 12, Issue 6, 2013, Pages 394-402

  Neijenhuis, Sari ^a   Bajrami, Ilirjana ^a   Miller, Rowan ^a   Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

MiRNA; Olaparib; PARP; RAD51; Radiation

Indexed keywords

MICRORNA; MICRORNA 107; MICRORNA 222; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; RAD51 PROTEIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DNA REPAIR; DRUG RESPONSE; HIGH THROUGHPUT SCREENING; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

DNA BREAKS, DOUBLE-STRANDED; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MCF-7 CELLS; MICRORNAS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RAD51 RECOMBINASE; RECOMBINATIONAL DNA REPAIR;

EID: 84877832362     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2013.02.003     Document Type: Article

References (38)

1. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411(6835):366-374.
2. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921.
3. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
4. Mendes-Pereira A.M., Martin S.A., Brough R., McCarthy A., Taylor J.R., Kim J.S., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1(6-7):315-322.
5. Forster M.D., Dedes K.J., Sandhu S., Frentzas S., Kristeleit R., Ashworth A., et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat. Rev. Clin. Oncol. 2011, 8(5):302-306.
6. McEllin B., Camacho C.V., Mukherjee B., Hahm B., Tomimatsu N., Bachoo R.M., et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010, 70(13):5457-5464.
7. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481(7381):287-294.
8. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1):15-20.
9. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
10. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482(7385):347-355.
11. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(9):2999-3004.
12. Blenkiron C. Miska EA. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum. Mol. Genet. 2007, 16. Spec no 1:R106-13.
13. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302(1):1-12.
14. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451(7182):1111-1115.
15. Iorns E., Turner N.C., Elliott R., Syed N., Garrone O., Gasco M., et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13(2):91-104.
16. Iorns E., Lord C.J., Turner N., Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 2007, 6(7):556-568.
17. Lord C.J., McDonald S., Swift S., Turner N.C., Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008, 7(12):2010-2019.
18. Brough R., Bajrami I., Vatcheva R., Natrajan R., Reis-Filho J.S., Lord C.J., et al. APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. EMBO J. 2012, 31(5):1160-1176.
19. Saeki H., Siaud N., Christ N., Wiegant W.W., van Buul P.P., Han M., et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(23):8768-8773.
20. Slabicki M., Theis M., Krastev D.B., Samsonov S., Mundwiller E., Junqueira M., et al. A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol. 2010, 8(6):e1000408.
21. Turner N.C., Lord C.J., Iorns E., Brough R., Swift S., Elliott R., et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008, 27(9):1368-1377.
22. Wilfred B.R., Wang W.X., Nelson P.T. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol. Genet. Metab. 2007, 91(3):209-217.
23. Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafre S.A., et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 2007, 282(32):23716-23724.
24. Pierce A.J., Johnson R.D., Thompson L.H., Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999, 13(20):2633-2638.
25. Sethupathy P., Corda B., Hatzigeorgiou A.G. TarBase: a comprehensive database of experimentally supported animal microRNA targets. RNA 2006, 12(2):192-197.
26. Sethupathy P., Megraw M., Hatzigeorgiou A.G. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat. Methods 2006, 3(11):881-886.
27. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
28. Betel D., Koppal A., Agius P., Sander C., Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010, 11(8):R90.
29. Betel D., Wilson M., Gabow A., Marks D.S., Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008, 36. (Database issue: D149-53).
30. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human MicroRNA targets. PLoS Biol. 2004, 2(11):e363.
31. Enright A.J., John B., Gaul U., Tuschl T., Sander C., Marks D.S. MicroRNA targets in Drosophila. Genome Biol. 2003, 5(1):R1.
32. Nagaraja A.K., Creighton C.J., Yu Z., Zhu H., Gunaratne P.H., Reid J.G., et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol. 2010, 24(2):447-463.
33. Linsley P.S., Schelter J., Burchard J., Kibukawa M., Martin M.M., Bartz S.R., et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol. Cell. Biol. 2007, 27(6):2240-2252.
34. Moskwa P., Buffa F.M., Pan Y., Panchakshari R., Gottipati P., Muschel R.J., et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 2011, 41(2):210-220.
35. Wang Y., Huang J.W., Calses P., Kemp C.J., Taniguchi T. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 2012, 72(16):4037-4046.
36. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11(12):849-864.
37. Doench J.G., Sharp P.A. Specificity of microRNA target selection in translational repression. Genes Dev. 2004, 18(5):504-511.
38. Liu H., Kohane I.S. Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy. PloS ONE 2009, 4(5):e5436.